A data-driven approach can identify distinct subgroups of HFpEF patients with different prognostic trajectories.
No takes yet. Share an insight, caveat, or question.
May refine HFpEF prognosis; leaves open whether subgroups guide therapy or require prospective validation.
Kao et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: